Direxion Daily Semiconductor Bull 3X Shares vs Zimmer Biomet Holdings Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $139.85 (market cap $24.42B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Direxion Daily Semiconductor Bull 3X Shares is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SOXL | ZBH | |
|---|---|---|
Market Cap | $24.42B | $16.95B |
Volume | 100,232,380 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $103.98 |
52-Week Low | $30.81 | $79.58 |
Typical Hold Time | 15 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $139.3, down 12.34% in the last 24 hours amid semiconductor sector volatility. Technical indicators show a bearish overall signal with mixed moving averages and neutral oscillators. The fund's leveraged structure amplifies both gains and losses in the semiconductor sector, which faces conflicting signals from strong AI demand versus concerns about valuation and regulatory risks.
The outlook for SOXL remains highly volatile, with opportunities tied to sustained AI-driven semiconductor demand but significant risks from the fund's 3x leverage structure and sector-specific headwinds. Investors face amplified exposure to semiconductor stock fluctuations, requiring careful risk management given the current bearish technical setup and mixed market sentiment.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →